Overview

• Verastem Q3 2025 net product revenue reaches $11.2 mln, marking successful product launch

• Company reports Q3 net loss of $98.5 mln, reflecting increased operating expenses

• VS-7375 trial shows promising preliminary results in KRAS G12D mutant solid tumors

Outlook

• Verastem expects cash runway into the second half of 2026

• Company plans to report interim safety and efficacy update on VS-7375 in 1H 2026

• Verastem plans to engage with FDA for potential trials in PDAC and NSCLC in 1H 2026

Result Drivers

• R&D - The increase of $4.2 million, or 16.9%, was primarily related to increased drug substance and drug product costs, increased contract research organization costs, and increased investigator trial costs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Verastem Inc is $14.00, about 29.3% above its November 3 closing price of $9.90

Press Release: ID:nBw6l9C2Ka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)